Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice

Neurochemical Research

Volumn 42, Issue 8, 2017, Pages 2326-2335

  Chen, Shuyi ^a   Sun, Jie ^a   Zhao, Gang ^a   Guo, Ai ^a   Chen, Yanlin ^a   Fu, Rongxia ^b   Deng, Yanqiu ^a,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN AGRICULTURAL UNIVERSITY   (China)

^c NONE   (China)

Author keywords

3 Tg mice; Alzheimer disease; ERK; JNK; Liraglutide; Tau

Indexed keywords

AMYLOID PRECURSOR PROTEIN; GLUCOSE; LIRAGLUTIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PRESENILIN 1; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; TAU PROTEIN; ANTIDIABETIC AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; DENTATE HILUS; DIET RESTRICTION; ESCAPE BEHAVIOR; GLUCOSE BLOOD LEVEL; HIPPOCAMPAL CA3 REGION; LATENT PERIOD; MALE; MEMORY; MORRIS WATER MAZE TEST; MOUSE; MOUSE MODEL; NERVE CELL DEGENERATION; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPATIAL LEARNING; TASK PERFORMANCE; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; GENETICS; INTERMEDIATE FILAMENT; MAZE TEST; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; RANDOMIZATION;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HYPOGLYCEMIC AGENTS; INTERMEDIATE FILAMENTS; LIRAGLUTIDE; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHORYLATION; PRESENILIN-1; RANDOM ALLOCATION; TAU PROTEINS;

EID: 85017097082     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-017-2250-8     Document Type: Article

References (39)

1. EsmaeiliTazangi P, Moosavi SM, Shabani M, Haghani M (2015) Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer’s disease. Pharmacol Biochem Behav 130:15–21
2. Blennow K, Zetterberg H, Fagan AM (2012) Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2:a006221
3. Liu Q, Xie F, Alvarado-Diaz A, Smith MA, Moreira PI, Zhu X et al (2011) Neurofilamentopathy in neurodegenerative diseases. Open Neurol J 5:58–62
4. Khan SS, Bloom GS (2016) Tau: the center of a signaling nexus in Alzheimer’s disease. Front Neurosci 10:31
5. Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer’s disease. Am J Pathol 175:2089–2098
6. Gerozissis K (2008) Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. Eur J Pharmacol 585:38–49
7. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R et al (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? J Alzheimers Dis 7:63–80
8. Egefjord L, Gejl M, Møller A, Brændgaard H, Gottrup H, Antropova O et al (2012) Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease - protocol for a controlled, randomized double-blinded trial. Dan Med J 59:A4519
9. Hansen HH, Barkholt P, Fabricius K, Jelsing J, Terwel D, Pyke C et al (2016) The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Res 1634:158–170
10. Sharma MK, Jalewa J, Hölscher C (2014) Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J Neurochem 128:459–471
11. Candeias EM, Sebastião IC, Cardoso SM, Correia SC, Carvalho CI, Plácido AI et al (2015) Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World J Diabetes 6:807–827
12. Xiong H, Zheng C, Wang J, Song J, Zhao G, Shen H et al (2013) The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. J Alzheimers Dis 37:623–635
13. Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, Vang K et al (2016) In Alzheimer’s disease, six-month treatment with GLP-1 analogue prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 8:108
14. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421
15. Shishido H, Kishimoto Y, Kawai N, ToyotaY, Ueno M, Kubota T et al (2016) Traumatic brain injury accelerates amyloid-beta deposition and impairs spatial learning in the triple-transgenic mouse model of Alzheimer’s disease. Neurosci Lett 629:62–67
16. Femminella GD, Edison P (2014) Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging. Alzheimers Dement 10:S55–S61
17. Vorhees CV, Williams MT (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1:848–858
18. Gadbury GL, Coffey CS, Allison DB (2003) Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev 4:175–184
19. McClean PL, Parthsarathy V, Faivre E, Hölscher C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci 31:6587–6594
20. Di J, Cohen LS, Corbo CP, Phillips GR, ElIdrissi A, Alonso AD (2016) Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss. Sci Rep 6:20833
21. Bertoni-Freddari C, Sensi SL, Giorgetti B, Balietti M, Di Stefano G, Canzoniero LM et al (2008) Decreased presence of perforated synapses in a triple-transgenic mouse model of Alzheimer’s disease. Rejuvenation Res 11:309–313
22. LaFerla FM, Oddo S (2005) Alzheimer’s disease: a-beta, tau and synaptic dysfunction. Trends Mol Med 11:170–176
23. Chen Y, Deng Y, Zhang B, Gong CX (2014) Deregulation of brain insulin signaling in Alzheimer’s disease. Neurosci Bull 30:282–294
24. Qi L, Ke L, Liu X, Liao L, Ke S, Liu X et al (2016) Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model. Eur J Pharmacol 783:23–32
25. Hansen HH, Fabricius K, Barkholt P, Kongsbak-Wismann P, Schlumberger C, Jelsing J et al (2016) Long-term treatment with liraglutide, a glucagon-like peptide-1 (GLP-1) Receptor agonist, has no effect on β-amyloid plaque load in two transgenic APP/PS1 mouse models of Alzheimer’s disease. PLoS ONE 11(7):e0158205
26. Mansur RB, Ahmed J, Cha DS, Woldeyohannes HO, Subramaniapillai M, Lovshin J et al (2017) Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mooddisorders: a pilot, open-label study. J Affect Disord 207:114–120
27. Yang Y, Zhang J, Ma D, Zhang M, Hu S, Shao S et al (2013) Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis 37:637–648
28. Li L, Zhang ZF, Hölscher C, Gao C, Jiang YH, Liu YZ (2012) (Val(8)) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol 674(2–3):280–286
29. Fernandez-Martos CM, King AE, Atkinson RA, Woodhouse A, Vickers JC (2015) Neurofilament light gene deletion exacerbates amyloid, dystrophic neurite, and synaptic pathology in the APP/PS1 transgenic model of Alzheimer’s disease. Neurobiol Aging 36:2757–2767
30. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA et al (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer’s disease and correction by insulin. J Neurosci Res 86:3265–3274
31. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M et al (2007) Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 27:13635–13648
32. Kim EK, Choi EJ (2015) Compromised MAPK signaling in human diseases: an update. Arch Toxicol 89:867–882
33. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H et al (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest 122(4):1339–1353
34. Giovannini MG, Cerbai F, Bellucci A, Melani C, Grossi C, Bartolozzi C et al (2008) Differential activation of mitogen-activated protein kinase signaling pathways in the hippocampus of CRND8 transgenic mouse, a model of Alzheimer’s disease. Neuroscience 153:618–633
35. Um HS, Kang EB, Koo JH, Kim HT, Jin-Lee, Kim EJ et al (2011) Treadmill exercise represses neuronal cell death in an aged transgenic mousemodel of Alzheimer’s disease. Neurosci Res 69:161–173
36. Yarza R, Vela S, Solas M, Ramirez MJ (2015) c-Jun N-terminal Kinase (JNK) signaling as a therapeutic target for Alzheimer’s disease. Front Pharmacol 6:321
37. Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ et al (2008) A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322:1539–1543
38. Arora K, Cheng J, Nichols RA (2015) Nicotinic acetylcholine receptors sensitize a MAPK-linked toxicity pathway on prolonged exposure to beta-amyloid. J Biol Chem 290:21409–21420
39. Ma QL, Harris-White ME, Ubeda OJ, Simmons M, Beech W, Lim GP et al (2007) Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer’s models. J Neurochem 103:1594–1607